June 26th, 2023 – Stonnington Group LLC has recently announced their new position in one of the leading biopharmaceutical companies, Apellis Pharmaceuticals, Inc. (NASDAQ: APLS). As per the latest 13F filing with the Securities and Exchange Commission (SEC), Stonnington Group LLC purchased 9,400 shares of APLS, valued at approximately $744,000 during the first quarter.
Apellis Pharmaceuticals is known for its disruptive work in discovering and developing therapeutic compounds that inhibit the complement system. The company’s mission is to solve debilitating autoimmune and inflammatory diseases through innovative medicines. Empaveli and Syfovre are two such innovative products offered by Apellis for solving severe geographical atrophy as well as other complex medical conditions like hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
APLS stock opened at $85.29 on Monday reflecting strong investment potential for shareholders. Apellis Pharmaceuticals enjoys a solid financial standing with a market capitalization of $9.93 billion and a debt-to-equity ratio of 0.23, well below industry standards. Additionally, it boasts a strong current ratio of 6.88 and quick ratio of 6.27 indicating that they have ample liquidity to meet short-term obligations.
The company’s outstanding performance can also be witnessed from its year-long stock prices trend where they achieved a high of $94.75, while maintaining an impressive low price at $42.15 over the past twelve months. Apellis’ stock price possesses favorable volatility with beta at an industry-leading rate of 1.25 compared to others in the pharmaceutical sector.
In conclusion, Stonnington Group LLC’s purchase of APLS shares demonstrates investors recognizing Apellis’ undiluted future growth potential despite challenges faced by biopharmaceuticals both economically and medically due to fluctuating pandemic circumstances worldwide. The innovative product range of Apellis, along with its strong financial standing, marks a strategic investment opportunity for discerning investors committed to socially responsible investments in the biotechnology industry.
[bs_slider_forecast ticker=”APLS”]
Institutional Investors and Hedge Funds Increase Stake in Apellis Pharmaceuticals as Company Pursues Growth with Flagship Drugs
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”APLS” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Apellis Pharmaceuticals, a biopharmaceutical company that develops therapeutic compounds to inhibit the complement system for autoimmune and inflammatory diseases, has recently seen an increase in its stock ownership by hedge funds and institutional investors. According to reports from June 26th, Avoro Capital Advisors LLC raised its ownership stake by 4.9% during the fourth quarter by purchasing an additional 500,000 shares worth $549,419,000. Vanguard Group Inc. and BlackRock Inc. also increased their stakes by 3.5% and 4.2%, respectively.
T. Rowe Price Investment Management Inc and State Street Corp were also among the institutional investors who had lifted their stakes in Apellis Pharmaceuticals by 5.9% and 20.3%, respectively.
In addition to a rise in stock ownership of Apellis Pharmaceuticals among institutional investors, recent insider trades have also been reported. On April 3rd, Karen Lewis sold 5,000 shares of the company’s stock for a total value of $375,000 at an average price of $75.00 per share.
The company’s flagship drugs are EMPAVELI that is used to treat paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD) ,amyotrophic lateral sclerosis (ALS), C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis (IC-MPGN) and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). It also offers SYFOVRE that treats geographic atrophy (GA).
Apellis Pharmaceuticals has recently released its quarterly earnings data on May 4th which revealed earnings per share ($1.56 EPS), missing the consensus estimate of ($1.42) by ($0.14); however, analysts predict that the firm will post -5.22 EPS for this fiscal year.
The company has also recently been the subject of a number of research reports from several investment analysts, four of which have rated the stock with a hold rating, eight have assigned a buy rating, and one has issued a strong buy rating to Apellis Pharmaceuticals as reported by Bloomberg.com.
In general, Apellis Pharmaceuticals is positioned for growth given the recent surge in institutional investment and significant investor interest in its flagship products.
